Charles River Laboratories Intl. Inc vs Rent the Runway Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Rent the Runway Inc trades at $1.77 (market cap $61.75M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 230.4× Rent the Runway Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Rent the Runway Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Rent the Runway Inc for 56 Days on average.
| CRL | RENT | |
|---|---|---|
Market Cap | $14.23B | $61.75M |
Volume | 1,176,885 | 193,323 |
Sector | Health | Consumer Cyclical |
52-Week High | $310.77 | $9.39 |
52-Week Low | $149.93 | $1.55 |
Typical Hold Time | 33 Days | 56 Days |
Enterprise Value | $17.06B | $228.75M |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
Rent the Runway (RENT) trades at $1.83, up 8.93% today, with a bullish technical signal despite mixed moving averages and oscillators. The company reported Q2 2026 revenue growth of 20.8% year-over-year to $97.7 million, with improving gross margins, and appointed Paige Thomas as CEO. However, the stock faces negative shareholder equity of -$182.5 million and a high debt-to-asset ratio of 139.62% as of 2025, though 2026 projections show a return to net profitability.
The outlook is cautiously optimistic, with analyst consensus at 42.1% buy ratings and no sell ratings, but legal investigations and high leverage pose significant risks. Revenue growth and margin expansion are key catalysts, yet investor confidence is tempered by ongoing financial instability and negative equity.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →